Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control Sep 20, 2023 08:30AM
Femasys to Participate in the H.C. Wainwright 25th Annual Global Investment Conference Sep 6, 2023 08:30AM
Femasys (FEMY) Obtains Medical Device Establishment License from Health Canada Aug 31, 2023 08:32AM
Femasys Inc. Obtains Medical Device Establishment License from Health Canada Aug 31, 2023 08:30AM
Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update Aug 10, 2023 08:00AM


Aug 3, 2023 08:46AM Femasys (FEMY) Initiates Enrollment in Trial of FemBloc
Aug 3, 2023 08:45AM Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc
Jul 27, 2023 08:45AM Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemBloc for Female Permanent Birth Control
Jun 26, 2023 08:04AM Femasys (FEMY) Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women
Jun 26, 2023 08:00AM Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women
Jun 15, 2023 08:00AM Femasys Inc. Replaces Two Board Members with Seasoned Industry Leaders in the Life Sciences
Jun 14, 2023 08:00AM Femasys to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023
Jun 8, 2023 08:34AM Femasys' (FEMY) FemCath Intrauterine Catheter Receives Product Approval in Canada
Jun 8, 2023 08:30AM Femasys’ FemCath Intrauterine Catheter Receives Product Approval in Canada
May 11, 2023 04:05PM Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2023
May 11, 2023 08:30AM Femasys Inc. to Showcase Four Products at the American College of Obstetricians and Gynecologists Annual Clinic & Scientific Meeting
May 11, 2023 08:30AM Femasys Inc. to Showcase Four Products at the American College of Obstetricians and Gynecologists Annual Clinic & Scientific Meeting
May 3, 2023 08:30AM Femasys’ FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada
May 1, 2023 04:05PM Femasys Inc. to Showcase FemCerv at the Annual Meeting for the American Society for Colposcopy and Cervical Pathology
May 1, 2023 04:05PM Femasys Inc. to Showcase FemCerv at the Annual Meeting for the American Society for Colposcopy and Cervical Pathology
Apr 18, 2023 08:05AM Femasys' (FEMY) FemaSeed Localized Directional Insemination for Infertility Receives Product Approval in Canada
Apr 18, 2023 08:00AM Femasys’ FemaSeed Localized Directional Insemination for Infertility Receives Product Approval in Canada
Apr 18, 2023 08:00AM Femasys’ FemaSeed Localized Directional Insemination for Infertility Receives Product Approval in Canada
Mar 30, 2023 08:00AM Femasys Inc. Announces Financial Results for the Year Ended December 31, 2022 and Provides Corporate Update
Mar 30, 2023 08:00AM Femasys Inc. Announces Financial Results for the Year Ended December 31, 2022 and Provides Corporate Update
Mar 9, 2023 08:00AM Femasys Inc. to Participate in “The Post-Roe Fertility Journey” Panel Discussion at SXSW 2023
Mar 9, 2023 08:00AM Femasys Inc. to Participate in “The Post-Roe Fertility Journey” Panel Discussion at SXSW 2023
Dec 19, 2022 09:00AM Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device
Dec 12, 2022 08:30AM Femasys Inc. Reports Encouraging Promotional Launch of FemCerv at AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons
Nov 29, 2022 07:00AM Femasys Inc. Announces Enrollment is over 25% Complete for FemaSeed® De Novo Trial Following Updated Strategic Study Design
Nov 21, 2022 08:30AM Femasys Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference
Nov 10, 2022 08:44AM Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update
Nov 10, 2022 08:44AM Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update
Oct 20, 2022 08:00AM Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement
Oct 14, 2022 04:05PM Femasys to Participate in 78th Annual American Society for Reproductive Medicine (ASRM) Scientific Congress
Oct 12, 2022 08:00AM Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs
Oct 6, 2022 08:01AM Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control
Oct 6, 2022 08:01AM Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control
Sep 29, 2022 08:00AM Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team
Sep 29, 2022 08:00AM Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team
Sep 1, 2022 04:05PM Femasys Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Sep 1, 2022 04:05PM Femasys Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Aug 10, 2022 04:05PM Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate Update
Aug 10, 2022 04:05PM Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate Update